Martina Caiazza

List of Publications by Citations

47 papers	242 citations	9 h-index	13 g-index
56 ext. papers	477 ext. citations	4.2 avg, IF	3.01 L-index

#	Paper	IF	Citations
47	Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2020**, 299, 186-191	3.2	32
46	Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	18
45	Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. *International Journal of Environmental Research and Public Health*, **2021**, 18,	4.6	17
44	Yield and clinical significance of genetic screening in elite and amateur athletes. *European Journal of Preventive Cardiology*, **2020**, 2047487320934265	3.9	16
43	Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes. *Frontiers in Pediatrics*, **2021**, 9, 632293	3.4	13
42	Genetic analysis resolves differential diagnosis of a familial syndromic dilated cardiomyopathy: A new case of Alstrm syndrome. *Molecular Genetics & Genomic Medicine*, **2020**, 8, e1260	2.3	11
41	Unexplained sudden cardiac arrest in children: clinical and genetic characteristics of survivors. *European Journal of Preventive Cardiology*, **2020**, 2047487320940863	3.9	11
40	Effects of Germline VHL Deficiency on Growth, Metabolism, and Mitochondria. *New England Journal of Medicine*, **2020**, 382, 835-844	59.2	10
39	Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism. *European Journal of Preventive Cardiology*, **2020**, 27, 1906-1908	3.9	10
38	Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy. *Genes*, **2020**, 11,	4.2	9
37	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases. *PLoS ONE*, **2020**, 15, e0233050	3.7	8
36	Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity. *International Journal of Environmental Research and Public Health*, **2020**, 17,	4.6	8
35	The Hidden Fragility in the Heart of the Athletes: A Review of Genetic Biomarkers. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
34	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization-the first insight from the AC-TIVE Study. *European Journal of Preventive Cardiology*, **2021**,	3.9	6
33	Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy. *Future Cardiology*, **2021**, 17, 647-654	1.3	5
32	Molecular Epidemiology of Mitochondrial Cardiomyopathy: A Search Among Mitochondrial and Nuclear Genes. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
31	Clinical significance of family history and bicuspid aortic valve in children and young adult patients with Marfan syndrome. *Cardiology in the Young*, **2020**, 30, 663-667	1	5

30	The Risk of Sudden Unexpected Cardiac Death in Children: Epidemiology, Clinical Causes, and Prevention. *Heart Failure Clinics*, **2022**, 18, 115-123	3.3	4
29	Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia. *Heart Failure Clinics*, **2022**, 18, 31-37	3.3	4
28	Diagnosis and Management of Cardiovascular Involvement in Fabry Disease. *Heart Failure Clinics*, **2022**, 18, 39-49	3.3	4
27	Clinical Manifestations of 22q11.2 Deletion Syndrome. *Heart Failure Clinics*, **2022**, 18, 155-164	3.3	4
26	Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy. *Heart Failure Clinics*, **2021**, 17, 303-313	3.3	4
25	External validation of the increased wall thickness score for the diagnosis of cardiac amyloidosis. *International Journal of Cardiology*, **2021**, 339, 99-101	3.2	4
24	Multimodality Imaging in Cardiomyopathies with Hypertrophic Phenotypes.. *Journal of Clinical Medicine*, **2022**, 11,	5.1	3
23	Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge. *Diagnostics*, **2021**, 11,	3.8	3
22	Cardiovascular Involvement in mtDNA Disease: Diagnosis, Management, and Therapeutic Options. *Heart Failure Clinics*, **2022**, 18, 51-60	3.3	3
21	Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis. *Heart Failure Clinics*, **2022**, 18, 73-87	3.3	3
20	Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve. *Pediatric Cardiology*, **2021**, 42, 1133-1140	2.1	2
19	Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patients with Cardiac Amyloidosis: Pathophysiological Implications and Role in Differential Diagnosis.. *Journal of Cardiovascular Echography*, **2021**, 31, 157-164	0.6	1
18	Imaging the "Hot Phase" of a Familiar Left-Dominant Arrhythmogenic Cardiomyopathy.. *Genes*, **2021**, 12,	4.2	1
17	The Role of New Imaging Technologies in the Diagnosis of Cardiac Amyloidosis. *Heart Failure Clinics* , **2022**, 18, 61-72	3.3	1
16	The Heart Muscle and Valve Involvement in Marfan Syndrome, Loeys-Dietz Syndromes, and Collagenopathies. *Heart Failure Clinics*, **2022**, 18, 165-175	3.3	1
15	Troponin T Mutation as a Cause of Left Ventricular Systolic Dysfunction in a Young Patient with Previous Surgical Correction of Aortic Coarctation. *Biomolecules*, **2021**, 11,	5.9	1
14	Advanced Heart Failure in Special Population-Pediatric Age. *Heart Failure Clinics*, **2021**, 17, 673-683	3.3	1
13	Thoracic Aortic Dilation: Implications for Physical Activity and Sport Participation. *Diagnostics*, **2022**, 12, 1392	3.8	1

12	Pancarditis as the Clinical Presentation of Eosinophilic Granulomatosis with Polyangiitis: A Multimodality Approach to Diagnosis. *Neurology International*, **2022**, 12, 133-141	0	0
11	Modified Body Mass Index as a Novel Nutritional and Prognostic Marker in Patients with Cardiac Amyloidosis. *Neurology International*, **2022**, 12, 185-197	0	0
10	MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease. *Neurology International*, **2021**, 11, 230-254	0	
9	Cardiac Amyloidosis: Diagnostic Tools for a Challenging Disease. *Neurology International*, **2021**, 11, 111-121	2	
8	Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference. *Neurology International*, **2022**, 12, 102-108	0	
7	Clinical and Molecular Characteristics of Patients with PLN R14del Cardiomyopathy: State-of-the-Art Review. *Neurology International*, **2022**, 12, 112-121	0	
6	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases **2020**, 15, e0233050		
5	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases **2020**, 15, e0233050		
4	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases **2020**, 15, e0233050		
3	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases **2020**, 15, e0233050		
2	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases **2020**, 15, e0233050		
1	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases **2020**, 15, e0233050		